Breast cancer patients who have lymph node-negative disease after neoadjuvant chemotherapy may be able to safely forgo adjuvant regional nodal irradiation (RNI).
The 5-year disease-free survival rate was similar among patients who received RNI and those who did not.
The lead researcher, Eleftherios Mamounas, disclosed ties to the biopharmaceutical industry.
Breast cancer patients who have lymph node-negative disease after neoadjuvant chemotherapy may be able to safely forgo adjuvant regional nodal irradiation (RNI), according to research presented at the 2023 San Antonio Breast Cancer Symposium. The trial included 1641 patients with lymph-node positive, nonmetastatic breast cancer. The 5-year disease-free survival rate was 88.3% among patients who received RNI and 88.5% among those who did not. The 5-year overall survival rate was 93.6% and 94.0%, respectively. There were no unexpected toxicities.
The lead researcher, Eleftherios Mamounas, disclosed ties to the biopharmaceutical industry. The study was supported by the National Cancer Institute of the National Institutes of Health. The researchers plan to continue long-term follow-up to strengthen their analysis. It is important to note that the decision to forgo RNI should be made on a case-by-case basis, considering the individual patient's condition and the potential benefits and risks of the treatment.
The researchers plan to continue long-term follow-up to strengthen their analysis.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(100%)
None Found At Time Of
Publication
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (100%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (20%)
Mamounas has served as a consultant for Genentech, Merck, Exact Sciences, TerSera Therapeutics, Biotheranostics Inc., and Sanofi; has been on the speaker's bureau for Genentech, Merck, and Exact Sciences; and owns stock in Moderna.
The study was supported by the National Cancer Institute of the National Institutes of Health.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(100%)
None Found At Time Of
Publication
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (100%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (80%)
Dr. Mamounas has served as a consultant for Genentech, Merck, Exact Sciences, TerSera Therapeutics, Biotheranostics Inc, and Sanofi; has been on the speaker's bureau for Genentech, Merck, and Exact Sciences; and owns stock in Moderna.
The trial included 1641 patients with lymph-node positive, nonmetastatic breast cancer. The 5-year disease-free survival rate was 88.3% among patients who received RNI and 88.5% among those who did not. The 5-year overall survival rate was 93.6% and 94.0%, respectively. There were no unexpected toxicities.
